Structural determinants of the hyperalgesic activity of myotoxic Lys49-phospholipase A2

Abstract Background Bothropstoxin-I (BthTx-I) is a Lys49-phospholipase A2 (Lys49-PLA2) from the venom of Bothrops jararacussu, which despite of the lack of catalytic activity induces myotoxicity, inflammation and pain. The C-terminal region of the Lys49-PLA2s is important for these effects; however, the amino acid residues that determine hyperalgesia and edema are unknown. The aim of this study was to characterize the structural determinants for the Lys49-PLA2-induced nociception and inflammation. Methods Scanning alanine mutagenesis in the active-site and C-terminal regions of BthTx-I has been used to study the structural determinants of toxin activities. The R118A mutant was employed as this substitution decreases PLA2 myotoxicity. In addition, K115A and K116A mutants which contribute to decrease cytotoxicity and the K122A mutant which decreases both myotoxicity and cytotoxicity were also used. The H48Q mutant which does not interfere with membrane damage or myotoxic activity was used to evaluate if the PLA2 catalytic site is relevant for the non-catalytic PLA2-induced pain and inflammation. Wistar male rats received intraplantar injections with mutant PLA2. Subsequently, hyperalgesia and edema were evaluated by the paw pressure test and by a plethysmometer. Native and recombinant BthTx-I were used as controls. Results Native and recombinant BthTx-I induced hyperalgesia and edema, which peaked at 2 h. The R118A mutant did not induce nociception or edema. The mutations K115A and K116A abolished hyperalgesia without interfering with edema. Finally, the K122A mutant did not induce hyperalgesia and presented a decreased inflammatory response. Conclusions The results obtained with the BthTx-I mutants suggest, for the first time, that there are distinct residues responsible for the hyperalgesia and edema induced by BthTx-I. In addition, we also showed that cytolytic activity is essential for the hyperalgesic effect but not for edematogenic activity, corroborating previous data showing that edema and hyperalgesia can occur in a non-dependent manner. Understanding the structure-activity relationship in BthTx-I has opened new possibilities to discover the target for PLA2-induced pain.

Structural determinants of the hyperalgesic activity of myotoxic Lys49-phospholipase A2

Background Bothropstoxin-I (BthTx-I) is a Lys49-phospholipase A2 (Lys49-PLA2) from the venom of Bothrops jararacussu, which despite of the lack of catalytic activity induces myotoxicity, inflammation and pain. The C-terminal region of the Lys49-PLA2s is important for these effects; however, the amino acid residues that determine hyperalgesia and edema are unknown. The aim of this study was to characterize the structural determinants for the Lys49-PLA2-induced nociception and inflammation. Methods Scanning alanine mutagenesis in the active-site and C-terminal regions of BthTx-I has been used to study the structural determinants of toxin activities. The R118A mutant was employed as this substitution decreases PLA2 myotoxicity. In addition, K115A and K116A mutants - which contribute to decrease cytotoxicity - and the K122A mutant - which decreases both myotoxicity and cytotoxicity - were also used. The H48Q mutant - which does not interfere with membrane damage or myotoxic activity - was used to evaluate if the PLA2 catalytic site is relevant for the non-catalytic PLA2-induced pain and inflammation. Wistar male rats received intraplantar injections with mutant PLA2. Subsequently, hyperalgesia and edema were evaluated by the paw pressure test and by a plethysmometer. Native and recombinant BthTx-I were used as controls. Results Native and recombinant BthTx-I induced hyperalgesia and edema, which peaked at 2 h. The R118A mutant did not induce nociception or edema. The mutations K115A and K116A abolished hyperalgesia without interfering with edema. Finally, the K122A mutant did not induce hyperalgesia and presented a decreased inflammatory response. Conclusions The results obtained with the BthTx-I mutants suggest, for the first time, that there are distinct residues responsible for the hyperalgesia and edema induced by BthTx-I. In addition, we also showed that cytolytic activity is essential for the hyperalgesic effect but not for edematogenic activity, corroborating previous data showing that edema and hyperalgesia can occur in a non-dependent manner. Understanding the structure-activity relationship in BthTx-I has opened new possibilities to discover the target for PLA2-induced pain.(AU)

Avaliação da expressão e ativação de receptores opióides após injúria periférica em ratos / Evaluation of expression and activation of opioid receptors after peripheral injury in rats

Este trabalho teve como objetivo avaliar os mecanismos envolvidos no aumento da eficácia analgesia da crotalfina (CRF), um peptídeo com atividade tipo opióide, na vigência de inflamação (prostaglandina E2/PGE2) ou lesão tecidual (constrição crônica do nervo isquiático/CCI). A PGE2 (intraplantar), em ratos, aumentou a expressão gênica e protéica de receptores opióides do tipo m e k, no gânglio da raiz dorsal (DRG) e nervo da pata (NP), quando comparado a animais naive. A CCI aumentou a expressão de receptores m e d, no DRG e diminuiu os níveis de receptores k. Embora a PGE2 e CCI, per se, não ativem receptores opióides o CRF e agonistas opióides acarretam maior ativação destes receptores na vigência de sensibilização por PGE2 e CCI. Ainda, o CRF ativa a via das MAPKs (ERK1/2 e JNK), apenas na presença de PGE2, efeito mediado por receptores do tipo k e PKCz. Estes dados mostram que a expressão e ativação de receptores opióides são diferentemente regulados pela injúria aguda ou crônica.

This study aimed to evaluate the mechanisms involved in the increased analgesic efficacy of crotalphine (CRP), an opioid-like peptide, under inflammation prostaglandin E2 (PGE2) and tissue injury (chronic constriction injury/CCI). PGE2 (intraplantar) in rats, increases the genic and proteic expression of m- and k-opioid receptors in the dorsal root ganglia (DRG) and nerve paw (NP), when compared to naïve rats. CCI up-regulates the expression of m and d -opioid receptors in DRG and NP. In contrast, k-opioid receptors were down-regulated by CCI. Although PGE2 and CCI, per se, do not activate opioid receptors, CRP and opioid agonists lead to a higher activation of these receptors in NP slices under PGE2 or CCI sensitization or in DRG cells incubated with PGE2. Moreover, CRP activates ERK1/2 and JNK MAPKs pathways, k-receptor and PKCz-mediated, only when the cells were pre-incubated with PGE2. These data indicate that the expression and activation of opioid receptors are distinctly regulated by the presence of acute or chronic injury.